发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer. 治疗三阴性乳腺癌的新辅助免疫疗法的当前和未来趋势。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-10 DOI: 10.2217/imt-2022-0277
Ramon Andrade de Mello, Kátia Roque Perez, Thais Pérez Vazquez
{"title":"Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer.","authors":"Ramon Andrade de Mello, Kátia Roque Perez, Thais Pérez Vazquez","doi":"10.2217/imt-2022-0277","DOIUrl":"10.2217/imt-2022-0277","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) comprises 15-20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathways conducive to more effective treatments. Currently, neoadjuvant treatment for TNBC relies on standard chemotherapy in conjunction with immunotherapy, given the improved response observed with this drug combination. This review delves into the latest therapeutic updates in TNBC treatment and explores potential advancements shaping the future landscape of this disease in the neoadjuvant setting.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"257-266"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Steroid-dependent polyarthritis induced by immune checkpoint inhibitor therapy successfully treated with bimekizumab. 免疫检查点抑制剂疗法诱发的类固醇依赖性多关节炎成功治愈了bimekizumab。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-24 DOI: 10.2217/imt-2023-0252
Robin Springer, Kristin Lange, Bernhard Homey, Stephan Meller, Harm-Henning Lindhof
{"title":"Steroid-dependent polyarthritis induced by immune checkpoint inhibitor therapy successfully treated with bimekizumab.","authors":"Robin Springer, Kristin Lange, Bernhard Homey, Stephan Meller, Harm-Henning Lindhof","doi":"10.2217/imt-2023-0252","DOIUrl":"10.2217/imt-2023-0252","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) are an integral part of modern-day cancer therapy. Along with a greatly improved antitumor response come a number of immune-related adverse events (irAEs), musculoskeletal irAEs rank among the less frequent manifestations. The mechanisms behind these events are poorly understood, and so far clear guidelines for therapeutic management beyond treatment with glucocorticosteroids are lacking. We present the case of a 72-year-old patient who developed a severe ICI-induced polyarthritis that could not be controlled by glucocorticosteroids. We initiated an immunomodulating therapy with the IL-17A/F/AF-inhibitor bimekizumab, which lead to a full clinical and sonographic remission.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"287-293"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139541075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies. 两项研究旨在了解阿伐卡塔哌啶是否对地理萎缩患者有效且安全：GATHER1 和 GATHER 2 研究的通俗摘要。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-25 DOI: 10.2217/imt-2023-0274
Glenn J Jaffe, Arshad M Khanani
{"title":"Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies.","authors":"Glenn J Jaffe, Arshad M Khanani","doi":"10.2217/imt-2023-0274","DOIUrl":"10.2217/imt-2023-0274","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a summary of two publications. One publication is about the GATHER1 study, which was published in the journal <i>Ophthalmology</i> in 2021. The other publication is about the GATHER2 study, which was published in the journal <i>The Lancet</i> in 2023. Both studies included adult participants with geographic atrophy (GA). GA is an advanced form of dry age-related macular degeneration (dry AMD). The participants in both studies each received treatment in one of their eyes. In both studies, the researchers wanted to learn if avacincaptad pegol (ACP) could help to slow the worsening of the participants' GA over time.</p><p><strong>What were the results?: </strong>In these studies, the researchers found that ACP helped to slow the growth of the GA area in the participants' eyes compared with a sham injection. Participants who received ACP had a similar ability to read differently sized letters on a chart 1 year after treatment compared with participants who received no ACP through a sham injection. In the GATHER1 study, none of the participants had serious medical problems in the eye that received the injection. In the GATHER2 study, 2 out of 225 participants (less than 1%) who received ACP had serious medical problems in the eye that received the injection. In the group who received the sham injection, 2 out of the 222 participants (less than 1%) had serious medical problems in the eye that received the sham injection.</p><p><strong>What do the results mean?: </strong>ACP could be a treatment option for people with GA. The results from several studies are needed to decide which treatments work best and are safest. Other studies may provide new information or different results. Always talk to a doctor before making any treatment changes.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"205-221"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139546343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials. 透视：将ctDNA纳入《实体瘤反应评估标准1.1》，用于II期免疫疗法临床试验。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-10 DOI: 10.2217/imt-2023-0184
Tulay Kus, Irfan Cicin
{"title":"A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials.","authors":"Tulay Kus, Irfan Cicin","doi":"10.2217/imt-2023-0184","DOIUrl":"10.2217/imt-2023-0184","url":null,"abstract":"<p><p>A consensus guideline, iRECIST, was developed by the Response Evaluation Criteria in Solid Tumours (RECIST) working group for the use of the modified RECIST version 1.1 in cancer immunotherapy trials. iRECIST was designed to separate pseudoprogression from real progression. However, this is not the only ambiguous situation. In clinical immunotherapy trials, stable disease may reflect three tumor responses, including real stable disease, progressive disease and responsive disease. The prediction of a \"<i>true complete/partial response\"</i> is also important. Much data has accumulated showing that ctDNA can guide decisions at this point; thus, integrating ctDNA into the RECIST 1.1 criteria may help to distinguish a true tumor response type earlier in patients treated with immunotherapy; however, prospectively designed validation studies are needed.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"319-329"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma. pembrolizumab与白蛋白结合型紫杉醇和奈达铂联合治疗晚期食管鳞状细胞癌的有效性和安全性。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-10 DOI: 10.2217/imt-2023-0188
Fang Yan, Longpei Chen, Mingzhen Ying, Jie Li, Qiang Fu
{"title":"Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma.","authors":"Fang Yan, Longpei Chen, Mingzhen Ying, Jie Li, Qiang Fu","doi":"10.2217/imt-2023-0188","DOIUrl":"10.2217/imt-2023-0188","url":null,"abstract":"<p><p><b>Objective:</b> This research aimed to assess the efficacy and safety of pembrolizumab (PBL) combined with albumin-bound paclitaxel (ab-Pac) and nedaplatin (NDP) for advanced esophageal squamous cell carcinoma (ESCC). <b>Methods:</b> A total of 47 ESCC patients were administered PBL or NDP on day 1 and ab-Pac on days 1 and 8, every 21 days for one cycle. Tumor and toxicities were evaluated every two cycles and every cycle, respectively. <b>Results:</b> The objective response rate was 68.1% and the disease control rate was 100%. The median follow-up was 16.7 months; median progression-free and overall survival were 12.6 and 19.9 months, respectively. <b>Conclusion:</b> The combination of PBL with ab-Pac and NDP proved to be an effective and safe treatment regimen for advanced ESCC.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"305-317"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma. SAFFRON-103：西曲替尼联合替赛珠单抗治疗抗PD-(L)1难治/耐药晚期黑色素瘤的Ib期研究。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-10 DOI: 10.2217/imt-2023-0130
Xuan Wang, Hongming Pan, Jiuwei Cui, Xiao Chen, Won-Hee Yoon, Matteo S Carlino, Xin Li, Hui Li, Juan Zhang, Jingchao Sun, Jun Guo, Chuanliang Cui
{"title":"SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma.","authors":"Xuan Wang, Hongming Pan, Jiuwei Cui, Xiao Chen, Won-Hee Yoon, Matteo S Carlino, Xin Li, Hui Li, Juan Zhang, Jingchao Sun, Jun Guo, Chuanliang Cui","doi":"10.2217/imt-2023-0130","DOIUrl":"10.2217/imt-2023-0130","url":null,"abstract":"<p><p><b>Aim:</b> Investigate TKI sitravatinib plus anti-PD-1 antibody tislelizumab in patients with unresectable/advanced/metastatic melanoma with disease progression on/after prior first-line anti-PD-(L)1 monotherapy. <b>Methods:</b> Open-label, multicenter, multicohort study (NCT03666143). Patients in the melanoma cohort (N = 25) received sitravatinib once daily plus tislelizumab every 3 weeks. The primary end point was safety and tolerability. <b>Results:</b> Treatment-emergent adverse events (TEAEs) occurred in all patients, with ≥grade 3 TEAEs in 52.0%. Most TEAEs were mild-or-moderate in severity, none were fatal, and few patients discontinued treatment owing to TEAEs (12.0%). Objective response rate was 36.0% (95% CI: 18.0-57.5). Median progression-free survival was 6.7 months (95% CI: 4.1-not estimable). <b>Conclusion:</b> Sitravatinib plus tislelizumab had manageable safety/tolerability in patients with anti-PD-(L)1 refractory/resistant unresectable/advanced/metastatic melanoma, with promising antitumor activity. <b>Clinical Trial Registration</b>: NCT03666143 (ClinicalTrials.gov).</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"243-256"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of sublingual immunotherapy on clinical and laboratory autoimmunity. 舌下免疫疗法对临床和实验室自身免疫的影响
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-12 DOI: 10.2217/imt-2023-0231
Andrzej Bozek, Szymon Mućka, Martyna Miodonska, Anna Zlik, Magdalena Mroz-Dybowska
{"title":"Effect of sublingual immunotherapy on clinical and laboratory autoimmunity.","authors":"Andrzej Bozek, Szymon Mućka, Martyna Miodonska, Anna Zlik, Magdalena Mroz-Dybowska","doi":"10.2217/imt-2023-0231","DOIUrl":"10.2217/imt-2023-0231","url":null,"abstract":"<p><p><b>Background:</b> There still are few data on the long-term safety of sublingual immunotherapy (SLIT). The aim of this study was to assess the appearance of autoimmune diseases in patients before and after SLIT. <b>Materials & methods:</b> New cases of autoimmune diseases were monitored. Patients in the SLIT group (n = 816) were compared with controls (n = 1096). <b>Results:</b> The new incidences of autoimmune diseases in the SLIT group were lower compared with the control group: 18 (2.2%) versus 58 (5.3%); p < 0.05. Systemic lupus erythematosus, psoriasis and Hashimoto appeared much more often in the control group. <b>Conclusion:</b> SLIT had no significant effect on the induction of autoimmune diseases.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"235-241"},"PeriodicalIF":2.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10844896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapy. 洞察肿瘤相关三级淋巴结构在癌症免疫疗法中的成熟异质性。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-19 DOI: 10.2217/imt-2023-0196
Wenhao Xu, Jianfeng Yang, Shiqi Ye, Wangrui Liu, Jiahe Lu, Aihetaimujiang Anwaier, Hailiang Zhang, Dingwei Ye
{"title":"Insights into the maturation heterogeneity of tumor-associated tertiary lymphoid structures in cancer immunotherapy.","authors":"Wenhao Xu, Jianfeng Yang, Shiqi Ye, Wangrui Liu, Jiahe Lu, Aihetaimujiang Anwaier, Hailiang Zhang, Dingwei Ye","doi":"10.2217/imt-2023-0196","DOIUrl":"10.2217/imt-2023-0196","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"131-134"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review. 银屑病关节炎中甲氨蝶呤与口服改变病情抗风湿药的联合治疗：系统综述。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-19 DOI: 10.2217/imt-2023-0139
Tyng-Shiuan Hsieh, Tsen-Fang Tsai
{"title":"Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review.","authors":"Tyng-Shiuan Hsieh, Tsen-Fang Tsai","doi":"10.2217/imt-2023-0139","DOIUrl":"10.2217/imt-2023-0139","url":null,"abstract":"<p><p><b>Background:</b> Oral conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), especially methotrexate, are the cornerstone of treating psoriatic arthritis (PsA). The use of csDMARDs with biologics has increased their efficacy in psoriasis. However, the combination of two oral DMARDs in patients with PsA has not been adequately reviewed. In this study, we explore the combinational use of methotrexate with DMARDs in PsA patients. <b>Materials & methods:</b> A review was conducted using Medline (PubMed), Embase, Web of Science and the Cochrane Library, covering articles up to February 2023. <b>Results & conclusion:</b> Nine studies comprising 1993 participants were included. The evidence supporting combination therapy remains limited. Combinational therapy could be considered in patients with inadequate response to monotherapy or no access to biologics.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"115-130"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives. 头颈部鳞状细胞癌的免疫疗法：现状与展望。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-02-01 Epub Date: 2023-12-21 DOI: 10.2217/imt-2023-0174
Amaury Daste, Mathieu Larroquette, Nyere Gibson, Matthieu Lasserre, Charlotte Domblides
{"title":"Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.","authors":"Amaury Daste, Mathieu Larroquette, Nyere Gibson, Matthieu Lasserre, Charlotte Domblides","doi":"10.2217/imt-2023-0174","DOIUrl":"10.2217/imt-2023-0174","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid cancers, including head and neck squamous cell carcinoma (HNSCC). First approved for second-line settings, ICIs are now used for the first-line treatment of HNSCCs, mainly in combination with standard chemotherapy. This review focuses on the results of the main phase III studies evaluating ICIs in recurrent or metastatic HNSCCs. The efficacy and indications according to the PD-L1 status, the main predictive biomarker, are discussed. The results of trials assessing ICI efficacy for locally advanced disease, including the neoadjuvant setting are also discussed. Finally, therapeutic combinations that are potential treatments for HNSCCs, including ICIs and targeted therapies such as anti-EGFR agents, are presented.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"187-197"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信